logo
Malawi battles mpox as cases of the infectious disease surge in Africa

Malawi battles mpox as cases of the infectious disease surge in Africa

The Guardian26-05-2025
Malawi's ministry of health has announced three new cases of mpox in the capital, Lilongwe, bringing the number of confirmed cases to 11 since the country's first was reported in April.
Malawi is one of 16 countries in Africa reporting mpox outbreaks as health officials battle with vaccine shortages as well as limited testing and hospital capacity.
The Public Health Institute of Malawi said the patients were aged between 17 and 41. 'Investigations are under way to establish the possible source of infection and trace contacts,' the department said in a statement last week.
The first cases in Malawi come after US government aid cuts to healthcare, including HIV programmes, badly hit the country and raised fears of an escalation of infectious diseases. HIV medication programmes have been severely depleted by the cuts, said Richard Mvula, spokesperson for the Lilongwe district health office.
'A commonality about these cases is that some were immunocompromised,' he said, adding that people who had been on ART (antiretroviral therapy) had stopped taking their medication because of shortages brought about by the US cuts.
HIV can worsen the risk and severity of mpox, while effective HIV treatment can help manage the risk. People living with HIV, especially those with uncontrolled viral loads, may experience a more severe form of mpox.
Malawi had been on alert since the global mpox outbreak began in 2022 in the Democratic Republic of the Congo and several other African countries.
The news of the first cases last month prompted fears of an outbreak. While most cases have been restricted to Lilongwe, a two-year-old was found with the condition in Mangochi district, about 150 miles (240km) from the capital.
While recorded cases remain low in Malawi, one of the poorest countries in the world, mpox has surged in the region overall. The Africa Centers for Disease Control and Prevention (Africa CDC) reports 52,082 cases since the beginning of 2025, with more than 1,770 deaths during the outbreak as a whole.
In a briefing to journalists last week, Africa CDC officials said they were seeing different patterns of transmission between countries. In Sierra Leone, where cases are rising 'exponentially', the clade IIb form of the virus is circulating. In the DRC and its neighbours it is clade Ia and Ib that dominate.
They said the continent would need about 6.4m doses of vaccine, but was still far from having that available, with only 1.3m received so far. They also highlighted a lack of testing capacity in many countries, and warned that in Sierra Leone patients were being treated two to a bed.
Malawi's health system faces many challenges, including long distances to clinics, insufficient funding, a shortage of equipment and a lack of qualified personnel. In March this year, the Joint UN Programme on HIV and Aids drew attention to the immediate risks of the US funding cuts on HIV programmes in Malawi.
The programme cited thousands of HIV prevention drugs (PrEP) which were expiring. It said the government has instructed the remaining implementer to continue with the scaling up of injectable PrEP but to only recruit new pregnant and lactating women.
The US government had been providing more than $350m (£282m) to Malawi annually, according to the US Department of State.
Knowledge of mpox around the country is low, reminiscent of the Covid-19 outbreak where myths were rife and people resorted to tree leaves and herbs to cure the symptoms. Thousands of people died.
A series of interviews across the capital showed most people have no knowledge of mpox. In central Lilongwe, taxi driver Steven Banda outlined what he knew.
'I came across an official from the ministry of health who was explaining about it and advised that we should be careful since it is dangerous. She described the symptoms including swellings, and mentioned some of the districts affected. I'm not aware of any cases in my area or seen anyone suffering from the disease. We don't know much about it,' he said.
Dr Victor Mithi, the president of Malawi's Society of Medical Doctors, said there is need for significant vigilance among practitioners within hospitals to make sure that 'as we perform our day-to-day clinical procedures, we are able to screen those patients that may be having this condition'.
'It is a big concern because in Malawi, most people live in crowded houses and still believe that as a form of expression of love, you need to shake hands, you need to hug people and all those things which are basically the risk factors in the transmission of this disease.'
Mithi said that with the lessons drawn from Covid-19 and other infectious diseases, Malawi had the capacity to manage mpox, at clinical and community level.
'The challenge exists though because of the withdrawal of the US aid; the capacity of our healthcare system is no longer the same. Almost 60% of our healthcare system is donor dependent, of which more than 50% of the donor aid was coming from [the US]. So the withdrawal means that our healthcare system is completely shaken, we are left in a state where we didn't build internal capacities to sustain ourselves,' Mithi added.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

The first time I tried weight-loss jabs, I made a huge mistake. I got it right in the end - this is what you MUST know about keeping the pounds off with Mounjaro
The first time I tried weight-loss jabs, I made a huge mistake. I got it right in the end - this is what you MUST know about keeping the pounds off with Mounjaro

Daily Mail​

time2 hours ago

  • Daily Mail​

The first time I tried weight-loss jabs, I made a huge mistake. I got it right in the end - this is what you MUST know about keeping the pounds off with Mounjaro

On paper, I was a success story. In just four months, I'd lost nearly two stone thanks to weight-loss injections, dropping from 72kg (11st 5lb) to 60kg (9st 6lb). But the scales didn't tell the whole truth. I was exhausted, weak and terrified that I would regain every ounce. Looking in the mirror didn't deliver the feeling of triumph it should have, either. My face still looked puffy, and I was even wearing the same size 14 clothes as when I started.

Pharmacies warn of unsustainable demand for weight loss medication
Pharmacies warn of unsustainable demand for weight loss medication

The Independent

time2 hours ago

  • The Independent

Pharmacies warn of unsustainable demand for weight loss medication

The booming demand for weight loss jabs may be unsustainable, pharmacists warn. Many more patients are interested in using weight loss medication than are actually suitable for treatment, according to the National Pharmacy Association (NPA), which represents more than 6,000 independent community pharmacies. Some 21% of people who were interviewed in a NPA-commissioned poll agreed they had attempted to access weight loss treatments in the last year, either online or in person at a pharmacy, rising to 35% of 16 to 34-year-olds. This is compared to only 7% of those over 55. There were also 41% who agreed they would opt for weight loss treatments on the NHS if they were made available to them. This figure rose to 64% among 25 to 34-year-olds, despite many of these patients being unlikely to be clinically eligible. The NPA says the poll, in which 2,002 people were interviewed, reflects an increasing demand for private and NHS weight loss services. NPA chairman Olivier Picard said: 'Weight loss jabs are one of the biggest drug innovations this century, but growing demand for weight loss treatment highlights the need to make sure this is appropriate for those who want it. 'It's clear from this polling that many more people are interested in getting weight loss jabs than would actually be suitable for treatment. 'We want to make sure supplies are carefully managed so that those in most clinical need can benefit from weight loss medication.' Spiralling demand, fuelled partly by social media, could see people being tempted to resort to unregulated online suppliers instead of regulated pharmacies staffed by medical professionals, they fear. Online suppliers may not be offering weight loss jabs alongside a structured programme aimed at helping them change their behaviour. Wegovy and Mounjaro are among a number of drugs that are recommended to help tackle obesity on the NHS. Mounjaro and Wegovy are licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) for use in patients with a BMI of over 30 or between 27 and 30 but with a weight-related co-morbidity. This occurs when an individual who has obesity develops another medical condition due to their weight. The NHS currently rolls out Mounjaro to patients with a BMI of over 40 and at least four co-morbidities, the NPA says. The NPA is calling for new regulations to protect patients buying weight loss medication online, so there is a full two-way consultation and all relevant historical medical records are reviewed before the treatment is prescribed. They are waiting for more details about the role pharmacies could play in the rollout of the NHS weight management programme. At least 85% of weight loss medication prescriptions were made by pharmacies in April this year, the NPA estimates. Mr Picard said: 'Pharmacists are experts in medication and many have extensive experience delivering weight loss injections as part of a package of care, including lifestyle advice. ' Pharmacies are well placed to help roll this treatment out on the NHS, and help people make the best use of these powerful medicines.'

Pharmacy warning of unsustainable demand for weight loss medication
Pharmacy warning of unsustainable demand for weight loss medication

The Independent

time3 hours ago

  • The Independent

Pharmacy warning of unsustainable demand for weight loss medication

The National Pharmacy Association (NPA) has issued a warning that the burgeoning demand for weight loss injections may be unsustainable, citing a significant mismatch between public interest and clinical suitability for the treatments. The NPA, which represents over 6,000 independent community pharmacies, highlighted this concern. A poll commissioned by the association revealed that 21 per cent of respondents had attempted to access weight loss treatments in the past year, either online or directly from a pharmacy. This figure surged to 35 per cent among 16 to 34-year-olds, contrasting sharply with just seven per cent of those over 55. There were also 41% who agreed they would opt for weight loss treatments on the NHS if they were made available to them. This figure rose to 64% among 25 to 34-year-olds, despite many of these patients being unlikely to be clinically eligible. The NPA says the poll, in which 2,002 people were interviewed, reflects an increasing demand for private and NHS weight loss services. NPA chairman Olivier Picard said: 'Weight loss jabs are one of the biggest drug innovations this century, but growing demand for weight loss treatment highlights the need to make sure this is appropriate for those who want it. 'It's clear from this polling that many more people are interested in getting weight loss jabs than would actually be suitable for treatment. 'We want to make sure supplies are carefully managed so that those in most clinical need can benefit from weight loss medication.' Spiralling demand, fuelled partly by social media, could see people being tempted to resort to unregulated online suppliers instead of regulated pharmacies staffed by medical professionals, they fear. Online suppliers may not be offering weight loss jabs alongside a structured programme aimed at helping them change their behaviour. Wegovy and Mounjaro are among a number of drugs that are recommended to help tackle obesity on the NHS. Mounjaro and Wegovy are licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) for use in patients with a BMI of over 30 or between 27 and 30 but with a weight-related co-morbidity. This occurs when an individual who has obesity develops another medical condition due to their weight. The NHS currently rolls out Mounjaro to patients with a BMI of over 40 and at least four co-morbidities, the NPA says. The NPA is calling for new regulations to protect patients buying weight loss medication online, so there is a full two-way consultation and all relevant historical medical records are reviewed before the treatment is prescribed. They are waiting for more details about the role pharmacies could play in the rollout of the NHS weight management programme. At least 85% of weight loss medication prescriptions were made by pharmacies in April this year, the NPA estimates. Mr Picard said: 'Pharmacists are experts in medication and many have extensive experience delivering weight loss injections as part of a package of care, including lifestyle advice. 'Pharmacies are well placed to help roll this treatment out on the NHS, and help people make the best use of these powerful medicines.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store